Better Therapeutics, Inc.
BTTX
$0.0002
$0.000.00%
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -26.69% | -13.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.97% | -21.29% | |||
| Operating Income | 23.97% | 21.29% | |||
| Income Before Tax | 22.79% | 18.90% | |||
| Income Tax Expenses | 200.00% | 0.00% | |||
| Earnings from Continuing Operations | 22.76% | 18.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 22.76% | 18.89% | |||
| EBIT | 23.97% | 21.29% | |||
| EBITDA | 27.75% | 23.77% | |||
| EPS Basic | 37.35% | 38.10% | |||
| Normalized Basic EPS | 37.39% | 38.10% | |||
| EPS Diluted | 37.35% | 38.10% | |||
| Normalized Diluted EPS | 37.39% | 38.10% | |||
| Average Basic Shares Outstanding | 23.32% | 31.01% | |||
| Average Diluted Shares Outstanding | 23.32% | 31.01% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
